European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

Foreword

These guidelines for Legally Defensible Workplace Drug Testing have been prepared and updated by the European Workplace Drug Testing Society (EWDTS)\(^1\).

The European Guidelines are designed to establish best practice procedures whilst allowing individual countries to operate within the requirements of national customs and legislation. The EWDTS recommends that all European laboratories that undertake legally defensible workplace drug testing should use these guidelines as a template for accreditation, in addition to meeting the general requirements of the international standard EN ISO/IEC 17025 and/or EN ISO 15189.

These guidelines are relevant to laboratory-based testing only. The EWDTS is aware that there are Point of Contact (POC) devices available. If organisations wish to use POC devices it is recommended that POC devices used should come with international or national approvals.

These guidelines follow current best practices and are constantly under review.

\(^{1}\) EWDTS: www.ewdts.org

EWDTS guidelines committee:
Beck, Olof (Sweden)
Bosch, Tessa (Netherlands)
Carmichael, Duncan (UK)
Fucci, Nadia (Italy)
George, Claire (UK)
Neuhofer, Michaela (Austria)
Piper, Mark (UK)
Salomone, Alberto (Italy)
Schielen, Wim (Netherlands)
Steinmeyer, Stefan (Germany)
Taskinen, Sanna (Finland)
Weinmann, Wolfgang (Switzerland)
# European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

## Table of Contents

1. General........................................................................................................4
   1.1 Introduction...............................................................................................4
   1.2 Objectives ................................................................................................4
   1.3 Scope .........................................................................................................4
   1.4 Service Provision .....................................................................................4
   1.5 Drug testing in Context .........................................................................5
   1.6 Outline of drug testing process ...............................................................5
2. Definitions .......................................................................................................7
3. Urine Collection .............................................................................................9
   3.1 Introduction .............................................................................................9
   3.2 Personnel ................................................................................................10
   3.3 Urine Collection Kits .............................................................................10
   3.4 Chain of Custody Form .........................................................................10
   3.5 Urine Collection Procedures .................................................................11
4. Laboratory Organisation ................................................................................11
   4.1 Personnel ................................................................................................12
   4.2 Laboratory Security ..............................................................................12
   4.3 Laboratory Head ....................................................................................13
   4.4 Authorising Scientist ...........................................................................13
   4.5 Laboratory Analyst ...............................................................................13
   4.6 Toxicologist ............................................................................................13
   4.7 Expert Witness .......................................................................................13
   4.8 Quality Manager ....................................................................................13
   4.9 Other Personnel .....................................................................................14
5. Laboratory Analysis Procedures ..................................................................14
   5.1 Process ....................................................................................................14
   5.2 Chain of Custody ....................................................................................14
   5.3 Sample receipt ........................................................................................14
   5.4 Sample processing ................................................................................15
   5.5 Urine Validity Testing ...........................................................................16
6. Analytical Methods and Validation ..............................................................17
   6.1 Acceptable Screening Techniques .........................................................17
   6.2 Laboratory Screening Tests ................................................................17
   6.3 Standardisation of Laboratory Screening Assays ...................................18
   6.4 Confirmation Tests ...............................................................................18
   6.5 Validation ................................................................................................19
   6.6 Authorisation and Reporting of Results ..............................................19
   6.7 Long-Term Storage of Samples ...........................................................20
   6.8 Records ..................................................................................................20
7. Quality Assurance and Quality Control .....................................................21

© EWDTS

All Rights Reserved. The copyright and database rights in this document are owned by the European Workplace Drug Testing Society (EWDTS).
European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

7.1 Quality Assurance ........................................................................................................ 21
7.2 Quality Control ................................................................................................................ 21
7.3 Laboratory Screening Tests ............................................................................................ 22
7.4 Confirmation tests ............................................................................................................. 23
   7.4.1 Identification ............................................................................................................ 23
   7.4.2 Confirmation of results ............................................................................................ 26
7.5 External Quality Assessment ......................................................................................... 26
7.6 Sub-contracting .............................................................................................................. 26
8 Interpretation of Results ..................................................................................................... 27
   8.1 Toxicology Review ......................................................................................................... 27
   8.2 Medical Review ............................................................................................................ 27
9 Challenges to Drug Test Results ...................................................................................... 28
10 Appendix A ....................................................................................................................... 30

Urine Collection Procedure

11 Appendix B ....................................................................................................................... 36

Example of a Donor’s Statement of Informed Consent

12 Appendix C ....................................................................................................................... 37

Some examples of fatal flaws in the Chain of Custody

13 Appendix D ....................................................................................................................... 38

Recommended Substances and Maximum Cut-Off Concentrations for Screening
Tests in Urine ......................................................................................................................... 38

14 Appendix E ....................................................................................................................... 40

Recommended Substances and Maximum Cut-Off Concentrations for
Confirmation Tests in Urine 40
European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

1 General

1.1 Introduction
These guidelines represent an overview of the best practice for European laboratories providing urine workplace drug testing services to maintain the legal defensibility of a drug test when tested by either an employment tribunal or a court of law. They are designed to ensure that the entire drug testing process is conducted to give accurate and reliable information about a donor's drug use.

1.2 Objectives
- To provide a common framework for European providers of workplace drug testing services.
- To promote standards by providing guidelines which are accepted at a European level.
- To ensure that the processes undertaken are capable of legal scrutiny.
- To provide safeguards to protect the dignity of the specimen donors and the validity of the specimen.
- To define common quality assurance and quality control criteria for laboratories that are capable of being accredited by an external body.
- To ensure that the entire drug testing process is conducted to give accurate and reliable information about drug use of the employee.

1.3 Scope
These guidelines consider the three key stages of the workplace drug testing process.
- Specimen collection: Obtaining the urine specimen from the donor
- Laboratory analysis: Analysis of the sample for the presence of drugs
- Interpretation: Review and interpretation of the analytical results

1.4 Service Provision
Where a service provider is contracted to deliver all the stages, they must ensure that the minimum criteria in this document are met in all the key areas.
In those instances where a customer may undertake some stages of the process within their own organisation (e.g. specimen collection or interpretation), the service provider has a 'duty of care' to ensure that the customer understands the full implications of the drug testing process.
European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

The service provider does not have the authority to make decisions regarding the fitness for work of any individual being tested. It is recommended that any issues related to fitness for work be referred to the company’s medical representative.

1.5 Drug testing in Context

It should be explained to any purchaser of a laboratory drug testing service that drug testing should form part of an overall drug policy, which the purchaser has agreed with his employees and should have in place before testing is initiated.

The service provider should have an effective company drugs policy in place. The policy may include drug testing of the staff involved in the analysis and reporting of workplace drug testing results.

1.6 Outline of drug testing process

Specimen collection

Urine specimens for legally defensible drug testing need to be collected under circumstances which respect the dignity of the individual whilst ensuring that the sample is freshly voided. Suitable records must be made when the specimen is collected to prove that the specimen collected and the sample received by the laboratory is one and the same. This is the first link in the chain of custody process which, when reconstructed at a later date, can be used to prove that the final result belongs to the specimen collected.

Analysis

When the sample is received at the laboratory, checks on the integrity of the sample are carried out. Providing the sample passes the integrity checks a portion of the sample is taken and screened for the presence of drugs. If the screen results are all negative no further analysis is necessary. However if the screen tests carried out indicate the possible presence of a drug (above a predefined cut-off level) a confirmation test to prove or disprove the presence of the drug indicated by the screening test must be carried out on another portion of the sample.

When a negative result is obtained, either after the screen or confirmation test, it can be reported to the customer. Positive results may require interpretation.
European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

Interpretation

A laboratory positive result may be due to other reasons than intake of illicit drugs (i.e. prescribed or over-the-counter medication or dietary causes). It requires interpretation that is best carried out by the laboratory toxicologist in conjunction with a qualified medical practitioner who can consult both with the donor and the donor’s medical practitioner.

Record keeping

Suitable records must be made during the analytical process to prove that the sample received by the laboratory and the sample, about which the final report is written, are one and the same. All samples which prove positive for the presence of drugs and all records of the analytical process, must be kept for an agreed period of time to allow for any challenges to be made regarding the findings.

If the customer requires an independent toxicological review, the laboratory must make available, if requested, the analytical data upon which it based its final report.
2 Definitions

For purposes of these guidelines the following definitions have been adopted:

<table>
<thead>
<tr>
<th>Definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adulteration</td>
<td>See Tampering</td>
</tr>
<tr>
<td>Aliquot</td>
<td>A fractional part of a sample used for testing. It is taken as a sample representing the whole sample.</td>
</tr>
<tr>
<td>Authorising Scientist</td>
<td>A person who reviews all pertinent data and quality control results in order to attest to the validity of the laboratory’s test reports.</td>
</tr>
<tr>
<td>Calibrator</td>
<td>A solution of known concentration used to calibrate a measurement procedure or to compare the response obtained with the response of a test sample/sample. The concentration of the analyte of interest in the calibrator is known within limits ascertained during its preparation. Calibrators may be used to establish a calibration curve over a range of interest.</td>
</tr>
<tr>
<td>Chain of Custody</td>
<td>Procedures to account for each specimen by tracking its handling and storage from point of collection to final disposal. These procedures require that the donor identity is confirmed and that a chain of custody form is used from time of collection to receipt by the laboratory. Within the laboratory appropriate chain of custody records must account for the samples until disposal.</td>
</tr>
<tr>
<td>Chain of Custody Form</td>
<td>A form used to document the procedures from time of collection until receipt by the laboratory.</td>
</tr>
<tr>
<td>Collecting officer</td>
<td>A person trained to collect specimens from donors.</td>
</tr>
<tr>
<td>Collection Site</td>
<td>A place where individuals present themselves for the purpose of providing a specimen for analysis.</td>
</tr>
<tr>
<td>Confirmation Test</td>
<td>An analytical procedure to identify and quantify the presence of a specific drug or metabolite which is independent of the initial test and which uses a different technique and chemical principle from that of the screen test in order to ensure reliability and accuracy.</td>
</tr>
<tr>
<td>Customer</td>
<td>The organisation requesting the drug testing service.</td>
</tr>
<tr>
<td>Cut-off</td>
<td>A concentration level set to determine whether the sample is positive or negative for the presence of a drug.</td>
</tr>
<tr>
<td>Donor</td>
<td>The individual from whom a urine specimen is collected.</td>
</tr>
<tr>
<td>Laboratory</td>
<td>The facility providing the analytical services to detect drugs of abuse.</td>
</tr>
<tr>
<td>Negative result</td>
<td>A result reported by laboratory that indicates that either no drug is present in the sample or that any drug present is below the cut-off.</td>
</tr>
</tbody>
</table>
### European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Positive result</strong></td>
<td>A result reported by the laboratory as positive means that there is conclusive evidence that a drug is present in the sample tested at level greater than or equal to the confirmation cut off concentration.</td>
</tr>
<tr>
<td><strong>Quality control sample</strong></td>
<td>A sample used to evaluate whether or not an analytical procedure is operating within pre-defined tolerance limits.</td>
</tr>
<tr>
<td><strong>Medical Review Officer (MRO)</strong></td>
<td>A medical physician responsible for receiving laboratory results from the drug-testing laboratory who has knowledge of substance abuse and has appropriate training or experience to interpret and evaluate an individual's positive test result, in light of declared information.</td>
</tr>
<tr>
<td><strong>Sample</strong></td>
<td>A representative portion of a specimen submitted to a laboratory for testing.</td>
</tr>
<tr>
<td><strong>Screening Test</strong></td>
<td>A test to eliminate negative samples from further consideration and to identify the presumptively positive samples that require confirmation testing.</td>
</tr>
<tr>
<td><strong>Service Provider</strong></td>
<td>The organisation contracted to provide the drug testing service. This may be a laboratory, or a third party providing other elements of the service, and contracting with a laboratory.</td>
</tr>
<tr>
<td><strong>Specimen</strong></td>
<td>The portion of urine that is collected from a donor.</td>
</tr>
<tr>
<td><strong>Standard (1)</strong></td>
<td>A reference material of known purity or a solution containing a reference material at a known concentration.</td>
</tr>
<tr>
<td><strong>Standard (2)</strong></td>
<td>An agreed protocol or procedure (e.g. EN ISO/IEC 17025 and/or EN ISO 15189)</td>
</tr>
<tr>
<td><strong>Standard Operating Procedure (SOP)</strong></td>
<td>A written document giving the detailed steps to be followed when undertaking a particular task (e.g. the analysis of a given drug in a urine sample).</td>
</tr>
<tr>
<td><strong>Tampering</strong></td>
<td>Any process by which an individual knowingly interferes with (or attempts to interfere with) the processes of specimen collection, transport or analysis with the intention of avoiding a legitimate test result. The actions undertaken can include (but are not limited to) the addition of water or foreign substances to the specimen, specimen substitution, damaging bottle seals or packaging and the deliberate consumption of interfering substances or copious volumes of water prior to specimen collection.</td>
</tr>
<tr>
<td><strong>Toxicologist</strong></td>
<td>A person responsible for interpreting a toxicological analytical result for the customer or the customer’s designated Medical Review Officer.</td>
</tr>
</tbody>
</table>
3 Urine Collection

3.1 Introduction

This is the first link in the chain of custody process which, when reconstructed at a later date, can be used to prove that the final result belongs to the specimen collected.

The collection process must be carried out by someone formally assessed as competent and authorised to carry out the collection. Standard Operating Procedures (SOPs) must be written for the collection process, the storage of collection devices, the training of Collecting Officers and the shipping of the collected specimen to the laboratory. These procedures must be followed precisely.

Collection procedures must cover the following aspects:

- Privacy and security of the specimen collection site
- Steps to ensure that the specimen collection is observed
- Steps to protect against tampering and adulteration
- Identification of the donor giving the specimen
- Evidence of the written informed consent of the individual to the analysis of the specimen (an example is given in Appendix).
- Disclosure of recent medication, or evidence that the individual was advised of the significance of recent medication.
- All information is considered as confidential.

All specimens for legally defensible drug testing must be collected under circumstances that respect the dignity of the individual whilst ensuring that the sample is freshly voided and has not been tampered with in any way. The collection site must be secure and the absence of potential interfering substances must be guaranteed. The validity of the sample has to be guaranteed.

Suitable records must be made when the specimen is collected to prove that the specimen collected and the sample received by the laboratory is one and the same.

Where the customer takes responsibility for the collection process, the service provider has a duty of care to ensure that these guidelines are understood.
3.2 Personnel
Specimens must be collected by suitably trained personnel (Collecting Officers). Although no health care professional education is required, a documented training, which includes a demonstration of competence, must be undertaken before collections are performed. The training must include, at a minimum, instructions on the following:

- The collection process
- The storage and transport conditions of samples
- The chain-of custody process
- Troubleshooting (e.g. refusal of the test, insufficient sample, suspicion of tampering of the sample)
- The responsibility of the collecting officer for maintaining donor privacy, confidentiality of information, and specimen integrity.
- Ethical issues, especially regarding the declaration by the donor of the present use of prescribed and over-the-counter medications.

On successful completion of collector training a person may begin performing collections.

3.3 Urine Collection Kits
The specimen collection kit should comprise the following components:

- Chain of custody form.
- A unique identifier that links the chain of custody form and sample bottles.
- Collection cup, demonstrably clean and unused.
- Temperature measurement device.
- At least two sample bottles, demonstrably clean and unused.
- Tamper-evident seal for each bottle.
- Packaging components that satisfy current postal and courier regulations.

3.4 Chain of Custody Form
The minimum information required on the Chain of Custody Form is:

- Unique identification to link the form to the specimen bottles (typically a barcode label or code number assigned to the sample).
- Information uniquely identifying the donor.
3.5 Urine Collection Procedures

The guidelines give the current best practice for the collection of urine specimens for analysis.

A detailed example of urine collection protocol is in appendix A.

The procedures must cover the following aspects:

- Identification of the individual giving the specimen.
- Sufficient information given to the donor about the meaning and content of the drug test to enable informed consent to be given to providing a sample for analysis.
- Privacy and security of the specimen collection site.
- Steps to ensure that the specimen is freshly voided.
- Steps to protect against tampering and adulteration.
- Situations to discard a sample and collect a new one (see Appendix A).
- Evidence of the written informed consent of the individual to the analysis of the specimen (see Appendix B).
- Disclosure of recent medication, or evidence that the individual was advised of the significance of recent medication.
European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

and every person must have agreed to the “confidentiality policy” of the institution (in written form).

4.1 Personnel

All personnel should adhere to the requirements of EN ISO/IEC 17025 and/or EN ISO 15189 International Standards and as such, only staff who are suitably qualified and whose competence has been formally assessed can work within the laboratory. The laboratory must maintain accurate job descriptions for managerial, technical and key support personnel involved in the analytical tests. The laboratory must keep records that establish the individual’s qualifications / competency for all functions performed. The individual’s file must include an up-to-date *curriculum vitae* listing educational qualifications and previous employment experience, training and competency assessment records for the current tasks performed. Personnel performing specific tasks shall be qualified on the basis of appropriate education, training, experience and/or demonstrated skills, as required.

All laboratory personnel must have received training in Health and Safety issues, the Control of Substances Hazardous to Health (COSHH) Regulations and other relevant legislation.

The key functions outlined below are identified as the minimum requirement for a laboratory to maintain EN ISO/IEC 17025 and/or EN ISO 15189 accreditation for the provision of Workplace Drug Testing services. It is acceptable for individuals to have responsibility to carry out more than one role. By virtue of the laboratory’s accreditation, it can be accepted that the appropriate qualifications for each role are in place.

NOTE: Role titles may vary between organisations, but the responsibilities will be remaining the same.

4.2 Laboratory Security

Drug testing laboratories must have a robust security system to ensure that no unauthorised personnel gain access to the laboratory processes or to areas where samples or records are stored as mentioned in EN ISO/IEC 17025 and/or EN ISO 15189.

Unescorted access to these secured areas must be limited to authorised individuals. The laboratory must maintain a record that documents the entry and exit of all visitors to the secured laboratory areas.
The laboratory must maintain a record of all staff who are authorised to enter the secure laboratory areas. This list must be reviewed and updated on a regular basis.
Sample bottles must be retained within the secure laboratory area until the disposal date.

4.3 Laboratory Head
There must be one person who has overall responsibility for the professional, organisational, educational, and administrative activities of the drug testing facility. This person is responsible for the day-to-day management of the drug testing laboratory. Some of the functions may be delegated to other appropriately qualified personnel but the overall responsibility for any delegated functions will remain with the designated Laboratory Head (typically the Laboratory Supervisor).

4.4 Authorising Scientist
A person responsible for the review and certification of pertinent data and quality control results, prior to release of accurate and reliable analytical results.

4.5 Laboratory Analyst
A person responsible for undertaking the day-to-day analytical procedures.

4.6 Toxicologist
A person responsible for interpreting a toxicological analytical result for the customer or the customer’s designated Medical Review Officer.

4.7 Expert Witness
A person to present evidence to administrative or disciplinary proceedings that are based on analytical results reported by the laboratory.

4.8 Quality Manager
A person responsible for quality assurance within the laboratory organisation.
4.9 Other Personnel
Other technical or non-technical staff who must have the necessary training and skills for the tasks assigned.

5 Laboratory Analysis Procedures
5.1 Process
When samples are received at the laboratory, initial checks on the sample’s chain of custody and appearance are carried out. If the sample passes these checks a portion of the sample in bottle "A" is taken and goes through initial screening tests for the presence of drugs. Further testing of sample validity may also take place at this point.
If the screening results are all negative (below a pre-defined cut-off level) no further analyses are necessary.
However, if the screening tests carried out indicate the possible presence of a drug (above a pre-defined cut-off level) a confirmation test to prove or disprove the presence of the drug indicated by the screening test must be carried out on another portion of the sample.

The screen-only presumptive positive test is not considered to be legally defensible, but may report preliminary presumptive positive results as local legislation allows. In the report it has to be mentioned that preliminary presumptive positive result may be false positive and needs confirmation.
If the first analysis is performed by a confirmation-level analysis (mass spectrometry), the positive findings have to be retested with another portion of the sample.

5.2 Chain of Custody
Laboratories must use chain of custody procedures to maintain control and accountability of samples from receipt through completion of testing, reporting of results, during storage, and continuing until final disposal of samples.
Chain of custody records must be maintained on paper or in computerised form.

5.3 Sample receipt
The laboratory should receive at least two sealed sample bottles and a corresponding chain of
custody form.
At least one of these (referred to, in this document, as the “B” bottle) must be retained unopened and stored in conditions that reflect the storage of the sample under test (referred to, in this document, as the “A” bottle).

When a sample is received in the laboratory:
- Incoming orders and samples must be registered by the laboratory.
- Incoming samples are immediately checked regarding completeness, intactness and suitability for testing.
- Its packaging must be examined for evidence of tampering in transit.
- The information on the sample bottles within the package must be compared with the information on the accompanying chain of custody form.
- Any discrepancies must be noted and, where appropriate, reported immediately to the customer. Some minor discrepancies may be tolerated in the documentation without termination of the analysis. These must be agreed with the customer prior to analysis and should be documented.
- Appendix C lists examples of fatal flaws in the chain of custody and is provided for guidance. Flaws of this nature would normally result in the sample not being tested.

5.4 Sample processing
Separate representative portions (aliquots) of the sample in bottle ‘A’ will be used for the screening and confirmation tests. The sample preparation should follow the standard operating procedure and the manufacturer’s instructions for the collection system being used. Aliquots must be taken in such a manner that excludes the possibility of contamination.

**Short term storage:** samples that are not currently undergoing analysis must be refrigerated at 2-8°C. Stability has to be investigated and appropriate measures undertaken to ensure the sample is valid for the analysis.

The A and the B samples must be stored under identical conditions.

The quality control requirements in section 7 must be satisfied when conducting either screening or confirmation tests, either on single samples or samples grouped in batches.
5.5 Urine Validity Testing

The aim of validity testing is to demonstrate that the sample submitted for analysis is urine. The validity of the sample must be checked either before or during the screening process. Creatinine should always be analysed. The laboratory may also test for pH, nitrite, other adulterants and use tests to check the adequate functioning of the antibody in the immunoassay.

**Determination of the creatinine concentration**

- If the creatinine concentration is less than or equal to 2.0 mmol/L (226 mg/l), the specific gravity must be determined. Acceptable values for specific gravity are 1.001 – 1.020.
- Samples with creatinine results within the range 0.5-2.0 mmol/L (56 -226 mg/l) and specific gravity results within range, should be reported as dilute. Because dilution of urine may cause false negative results, a comment should be added to negative drug testing results. Samples which screen positive will be confirmed normally and reported if positive (over the pre-defined cut-off value).
- Samples with creatinine results less than or equal to 0.5 mmol/L (56 mg/l) and/or specific gravity results out of range may be unsuitable for testing and should be reported as e.g. “sample integrity failed”. Samples which screen positive will be confirmed normally and reported if positive (over the pre-defined cut-off value). Negative drug testing results should not be reported.

**Measurement of pH**

- Results within the range 4-9 are deemed to be within a normal range. Results less than 3 or greater than 11 should be considered to be adulterated. Samples falling outside this range should be reported as e.g. “sample integrity failed”.
- Samples with pH values outside the normal range which screen positive will be confirmed normally and reported if positive (over the pre-defined cut-off value). Negative drug testing results should not be reported.
Nitrite test: if the nitrite concentration is determined

- A nitrite level equal to or above 500 µg/mL is conclusive proof of an adulterated sample. The result should be reported as e.g. “sample integrity failed”.
- Samples with nitrite concentrations above this level which screen positive will be confirmed normally and reported if positive (over the pre-defined cut-off value). Negative drug testing results should not be reported.

Testing for other adulterants

- If other tests indicate that the sample has been adulterated, or is otherwise unsuitable for analysis then it should be reported as e.g. “sample integrity failed”
- This remark is also reported when the sample does not fall under the criteria of pH, creatinine or nitrite above, yet is still not suitable for testing. This can be due to an unidentified interferent or poor sample quality such as turbidity.

6 Analytical Methods and Validation

6.1 Acceptable Screening Techniques

Following methods are accepted e.g.:

- Immunoassays
- Gas Chromatography
- High Performance Liquid Chromatography
- All chromatographic techniques coupled to mass spectrometry.
- Capillary Zone Electrophoresis

6.2 Laboratory Screening Tests

The initial screening test must use an appropriate technique. The assay using the selected technique must be validated prior to its use.

Recommended maximum screening cut-off concentrations for workplace drug testing are listed in Appendix D. These recommended cut-off concentrations may be subject to change reflecting advances in technology and knowledge.

Cut-off concentrations for substances not indicated in Appendix D will need to be agreed with the customer taking into account the performance of the assays to be used and the pharmacokinetics
of the drugs involved.

All screening test results must be reviewed with regard to the results of the validity tests performed. Samples that test negative on all the initial screening tests and pass the validity tests must be reported as negative and the samples can be disposed of as agreed with the customer. Samples that test negative on all the initial screening tests but fail the validity tests may be further investigated to determine the reason why.

The presumptive presence for any drug following the initial preliminary screen must have the presence of the drug confirmed (refer to section 6.4 Confirmation Tests). If the first analysis is performed by a confirmation-level analysis (mass spectrometry), the positive findings have to be confirmed and quantified by reanalysis with another portion of the sample.

### 6.3 Standardisation of Laboratory Screening Assays

All assays must be calibrated against appropriate standards by following laboratory protocols based on the manufacturer’s recommendations or validated alternatives.

The assay must be calibrated against one named compound, and the cross-reactivity to other related compounds must be determined.

The customer must be informed of the limitations of the tests.

### 6.4 Confirmation Tests

The presence of the drugs indicated by a positive screening result must be confirmed using a chromatographic technique in combination with mass spectrometry (e.g. GC-MS or LC-MS). If the first analysis is performed by a confirmation-level analysis (mass spectrometry), the positive findings have to be confirmed and quantified by reanalysis with another portion of the sample.

All confirmations must be quantitative. The customer must be informed of the compounds detected in the confirmation tests.

Recommended confirmation cut-off concentrations for workplace drug testing are given in Appendix E.

Confirmation cut off concentrations may be subject to change as advances in technology or other considerations warrant identification of substances at other concentrations. Confirmation cut-off levels for substances not indicated in Appendix E must be agreed with the
customer taking into account the performance of the assays to be used and the pharmacokinetics of the drugs involved.

Samples that are below the agreed cut-off concentration must be reported negative. No further testing for drugs will be undertaken and the samples must be discarded.

Samples that contain drugs and/or metabolites at concentrations greater than or equal to the agreed cut-off level must be reported as positive.

Laboratories must adhere to national and international guidelines that specify additional criteria for chromatographic and mass spectral acceptability.

6.5 Validation

All methods must be validated and their suitability for intended purpose must be evaluated in accordance with EN ISO/IEC 17025 and/or ISO 15189 requirements.

The following parameters have to be determined at least for quantitative confirmation analyses and whenever possible, for screening analyses: precision, cut-off verification, selectivity, limit of detection, limit of quantification, sensitivity, specificity, stability, measurement uncertainty and matrix effects.

6.6 Authorisation and Reporting of Results

Before any laboratory test result is released, the results must be reviewed and certified as accurate by a competent member of staff (analytical validation). At a minimum, the report must include the specimen identification number and the test result (positive/negative) for each sample submitted.

Reporting must be managed in accordance with EN ISO/IEC 17025 and/or ISO 15189 requirements. In addition the cut-off used for the test should be included.

Only drugs that have been confirmed by a recognised confirmation test can be reported as positive.

Samples that fail integrity or validity tests must be identified to the customer on the report. The laboratory must define and agree the meaning of all terms used in the report to the customer. Results must be transmitted to the customer’s designated representative in a manner that will ensure confidentiality of the information. Laboratory results should not be provided verbally. Written or electronic results must be transmitted to the customer’s designated representative in a manner that will ensure confidentiality of the information.
6.7 Long-Term Storage of Samples
The laboratory must demonstrate that the long term storage conditions of samples are adequate to ensure that analytes are stable over the time period required for any re-test. Currently long-term frozen storage (−20°C or below) indicates that most positive samples will remain suitable for any necessary retest.

Unless otherwise authorised in writing by the customer, drug testing laboratories must retain all samples confirmed positive in properly secured long-term frozen storage for a minimum of 1 year. Within this one-year period the customer may request the laboratory to retain the sample for an additional period of time. If no such request is received, the laboratory may discard the sample after the end of 1 year. The laboratory shall be required to maintain any samples known to be under legal challenge for a further agreed period. Samples must be retained within the secure laboratory area until the disposal date agreed with the customer. Negative samples (A+B) may be discarded as per the laboratory and customer agreed timetable.

6.8 Records
The laboratory must maintain and make available for an agreed period, documentation of all aspects of the testing process involved in the generation of a positive result.

The required documentation must include:
- Training and competency records for all individuals authorised to have access to samples and sample data
- Chain of custody forms
- Quality assurance/quality control records
- Standard operating procedures
- All test data (including calibration curves and calculations used in determining test results)
- Maintenance and instrument calibration records
- Reports
- Records of proficiency testing and computer generated data
The laboratory will be required to maintain documents for any sample under legal challenge for a further agreed period.

Document control must be managed in accordance with EN ISO/IEC 17025 and/or EN ISO 15189 requirements and records containing details of individuals should be dealt with in line with European Data Protection Legislation.

7 Quality Assurance and Quality Control

7.1 Quality Assurance

Drug testing laboratories must have a quality management system which encompasses all aspects of the testing process including but not limited to:

- Sample receipt
- Chain of custody
- Security and reporting of results
- Screening and confirmation testing
- Certification of calibrators and controls
- Validation of analytical procedures

Quality assurance procedures shall be designed, implemented and reviewed to monitor the conduct of each step of the testing process.

The testing laboratory and all screening and confirmation tests used in Workplace Drug Testing must be fully validated and when possible accredited (EN ISO/IEC 17025 and/or EN ISO 15189) by a recognised external accreditation body. When an unaccredited method is used the customer should be informed accordingly.

7.2 Quality Control

Calibrators and controls shall be prepared using either certified drug reference materials or certified standard solutions obtained from where possible two commercial manufacturers and should be appropriate to the matrix. If two manufacturers are not feasible then the controls should be taken from separate lots from the same manufacturer.
The laboratory must retain records to demonstrate that all calibrators and controls are traceable back to primary standards (if available).

The calibrators and controls shall be properly labelled as to content, concentration, date placed in service and expiry date.

All standards (e.g. pure reference materials, stock standard solutions, purchased standards) shall be labelled with the following:

- Date received (if applicable).
- Date prepared or opened or placed in service.
- Expiration date.
- Lot number of drug reference materials.
- Initials of the technicians who has prepared the (in house) calibrator etc.

All data acquired on control samples must be recorded in such a way as to facilitate interpretation of control results and trends.

### 7.3 Laboratory Screening Tests

These are the minimum requirements for the suitable control of all laboratory screening tests. A system suitability check must be carried out prior to the analysis of samples.

Assays must be calibrated weekly or when quality control samples indicate poor performance.

Control samples at concentrations of approximately 25% below and above the cut-off concentration for each drug group must be included in every batch of samples. These must be sourced independently from calibrators.

Quality control samples must comprise at least 5% of the total number of samples in each batch being analysed.
7.4 Confirmation tests

These are the minimum requirements for identification of analytes and confirmation of results.  

7.4.1 Identification

Mass spectrometry coupled to chromatography

a) Mass spectrometry coupled to a chromatographic separation method is a very powerful combination for identification of an analyte in the sample extract. It simultaneously provides retention time, ion/charge ratios and relative abundance (intensity) data.

Requirements for chromatography

b) The minimum acceptable retention time for the analyte(s) under examination should be at least twice the retention time corresponding to the void volume of the column. The retention time of the analyte in the extract should correspond to that of the calibration standard (may need to be matrix-matched) with a tolerance of ± 1 %, for both gas chromatography and liquid chromatography.

Tolerance 1% means (with rt: retention time):

\[
\frac{rt_{\text{analyte in sample}} - rt_{\text{analyte in calibrator}}}{rt_{\text{analyte in calibrator}}} \leq 0.01
\]

Requirements for mass spectrometry (MS)

c) Reference spectra for the analyte should be generated using the same instruments and techniques used for analysis of the samples. If major differences are evident between a published spectrum and the spectrum generated within the laboratory, the latter must be shown to be valid.

d) Identification relies on proper selection of diagnostic (characteristic) ions. The (quasi) molecular ion is a diagnostic ion that should be included in the measurement and identification procedure whenever possible. In general, and especially in single-stage MS, high m/z ions are more specific than low m/z ions (e.g. m/z < 100).
e) Extracted ion chromatograms of sample extracts should have peaks (exceeding S/N 3:1 of similar retention time, peak shape and response ratio to those obtained from a calibration standard analysed at comparable concentration in the same batch. Shift in retention time should not exceed 1% compared to calibration standard. Chromatographic peaks from different selective ions for the same analyte must overlap with each other. Where an ion chromatogram shows evidence of significant chromatographic interference, it must not be relied upon to quantify or identify residues. The ion that shows the best signal-to-noise ratio and no evidence of significant chromatographic interference should be used for quantification.

f) In case of full scan measurement, careful subtraction of background spectra, either manual or automatic, by deconvolution or other algorithms, may be required to ensure that the resultant spectrum of the chromatographic peak is representative. Whenever background correction is used, this must be applied uniformly throughout the batch and should be clearly indicated.

g) Different types and modes of mass spectrometric detectors provide different degrees of selectivity and specificity, which relates to the confidence in identification. General requirements for identification by MS-methods have been published and should be regarded as guidance criteria for identification, not as absolute criteria to prove presence or absence of a compound.

h) The relative intensities or ratios of selective ions (full-scan MS or SIM) or product ions (MS/MS), expressed as a ratio relative to the most intense (product) ion, should correspond to those of the calibration standard at comparable concentrations and measured under the same conditions. Matrix-matched calibration solutions may need to be used. Table 2 below indicates the maximum tolerances for ion ratios.

i) The variability of ion ratios should preferably be determined from calibration standards during initial method validation and subsequently during routine analysis. Diagnostic ions should have an ion ratio of > 0.05 (least/most intense ion).

3 Reference see footnote on page 23
Table 2: Recommended maximum tolerances for ion ratios using different MS techniques

<table>
<thead>
<tr>
<th>Ion ratio (least/most intense ion)</th>
<th>Maximum tolerance (relative) for GC-EI-MS</th>
<th>Maximum tolerance (relative) for GC-CI-MS, GC-MS, LC-MS, LC-MS&lt;sup&gt;n&lt;/sup&gt;</th>
<th>&lt;sup&gt;**&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;50%</td>
<td>20%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>&gt;20-50%</td>
<td>20%</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>&gt;10-20%</td>
<td>25%</td>
<td>30%</td>
<td></td>
</tr>
<tr>
<td>≤10%</td>
<td>50%</td>
<td>50%</td>
<td></td>
</tr>
</tbody>
</table>

j) At higher deviation of the relative abundance of a qualifier ion, analysis needs to be repeated. If tolerances still remain beyond acceptance criteria, further investigation of influences of matrix effects or disturbing compound are recommended – such as standard addition experiments or chance of chromatographic system - to verify or to exclude the presence of a compound. In these cases complementary interpretation by an experienced analyst is recommended.

k) For a higher degree of confidence in identification, further evidence may be achieved from additional mass spectrometric information. For example, evaluation of full scan spectra, isotope pattern, adduct ions, additional accurate mass fragment ions, additional product ions (in MS/MS), or accurate mass product ions.

For High resolution (HRMS) the mass resolution shall typically be greater than 10000 for the entire mass range at 10% valley (which equates to resolving power of 20000 FWHM (full width at half maximum).

For accurate mass measurements (AMM) the instrument mass error in routine mass measurements must be less than 2 mDa and resolution shall typically be greater than 5000 FWHM.
European Guidelines for Workplace Drug Testing in Urine

For combination of LC with HR-QToF-MS/MS or other mass spectrometric technique with HR-MS/MS the following settings are recommended for mass spectral identification based on a mass spectral library (commercial or home-made):

For HR-QToF-MS/MS analysis a mass resolution of > 10000 amu with a mass accuracy of < 5 ppm and an isotope ratio comparability of better than 80% should be used in routine analysis. If comparison to a library is performed with MS/MS spectra, a fit value of > 70 % should be used as a threshold, for identification of compounds. Additionally, 1% tolerance of LC-retention time is required (see above, e).

1) The chromatographic profile of the isomers of an analyte or any relevant metabolites may also provide evidence. Additional evidence may be sought using a different chromatographic separation system and/or a different MS-ionisation technique.

7.4.2 Confirmation of results

m) If the initial analysis does not provide unambiguous identification or does not meet the requirements for quantitative analysis, a confirmatory analysis of the A-sample is required. This may involve reanalysis of the extract or the sample. In cases where a detection threshold for a drug is exceeded, a confirmatory analysis of a portion of the B-sample may be required by the authorities. For unusual analyte/matrix combinations, a confirmatory analysis is also recommended.

n) The use of different determination techniques and/or confirmation of qualitative and/or quantitative results by an independent expert laboratory will provide further supporting evidence.

7.5 External Quality Assessment

The laboratory must take part in appropriate external quality assessment schemes. When the scheme is not available, the laboratory has to conduct appropriate inter-laboratory testing to ensure appropriate assay performance.

7.6 Sub-contracting

Drug testing laboratories should carry out all laboratory work with their own personnel and
equipment. If it is necessary to sub-contract, inter-laboratory transfer of samples is performed with strict adherence to chain of custody procedures. The sub-contracted laboratory and its methods used must be accredited by a recognised external accrediting body and compliant with these guidelines. Analyses undertaken by sub-contracted laboratories must be identified on the test report to the customer.

8 Interpretation of Results

A confirmed analytical positive result may be due to medication (prescribed or over-the-counter) or due to dietary causes. An essential part of the drug testing process is the final review of analytical results.

The interpretation is best carried out by a qualified medical professional (e.g. Medical Review Officer) or a Toxicologist (depending on the country-specific situation) who can consult with the donor and the donor’s medical practitioner (See chapter 4).

8.1 Toxicology Review

It is mandatory that a toxicologist is available to advise the customer and/or Medical Review Officer regarding queries with test results.

8.2 Medical Review

The Medical Review Officer (MRO) is a medical physician with responsibility for interpreting laboratory results together with a toxicologist. Depending on the country-specific situation a medical physician usually has greater access to medical records than a toxicologist and may therefore be in a better position to provide interpretation of positive analytical results.

The MRO must have specialist knowledge of and training in

- specimen collection procedures,
- analytical procedures,
- chain of custody and
- alternative explanations for positive analytical results.
The MRO can issue a negative report for a positive analytical result if the test result is likely to be due to the use of declared medication, or a valid alternative explanation has been found. The service provider may provide access to an independent medical review service.

9 Challenges to Drug Test Results

In situations where there is a challenge to the results of a confirmed positive drug test result, the following guidelines must be used.

The B sample should be released for analysis to a drug testing laboratory accredited by a recognised external accrediting body and working to these guidelines. This release requires authorisation from both the customer/MRO and the donor. The release must be supported by chain of custody procedures that can withstand legal scrutiny and include information about the findings of the original test (corresponding A sample) and the cut-offs used for the test.

The original laboratory must retain the residue of the original sample and its containers so that they can be compared with the B sample at a later date if required. All laboratories that undertake B sample testing must be able to demonstrate that they can accurately determine the concentration of a drug or metabolite at 50% of the recommended confirmation cut-off concentration listed in Appendix E (or the cut-off used for the original test, whichever is the lower).

On receipt in the testing laboratory, the B sample should follow chain of custody procedures as outlined. It is recommended that the laboratory should carry out validity checks outlined prior to carrying out the confirmation analysis. Only those drugs identified for confirmation testing should be looked for.

The final report on the B sample must say either that there was no drug found, or a named drug was found at a level that is either consistent or inconsistent with the level in the corresponding A sample. Confirmation cut-off levels are not to be used as the determinant. There must be no comment on the final report that states whether the sample is positive or negative.
The final interpretation of the results is done by a Medical Review Officer together with a toxicologist.
10 Appendix A

Urine Collection Procedure

(Note: Only formally competence tested and authorised persons may act as collecting officers. Medical qualification is NOT required for collecting officers.)

I. Collection Site

Procedures shall provide for a designated collection site to be secure. During the collection process the collection site must be dedicated solely to sample collection and comply with all local health and safety requirements.

The circumstances of the collection site should be arranged so that the adulteration of the sample is prevented as well as possible. To deter the dilution of specimens at the collection site, toilet water colouring agents should be placed in toilet tanks wherever accessible or in the toilet bowl, so the reservoir of water in the toilet bowl always remains coloured. Any other sources of water in the enclosure where urination occurs (e.g. taps, shower) will be secured prior to collection. At the collection site access must be controlled to soap dispenser, cleaning agent, or any other materials that could be used to adulterate the specimen.

II. Access to Authorised Personnel Only

Only authorised personnel shall be permitted in any part of the designated collection site when urine samples are being collected or stored. The donor has the right to be accompanied with a silent witness, but that should not interfere or delay the collection process.

III. Chain of Custody

During the collection process chain of custody forms will be completed fully by the collecting officer and donor.

IV. Identification of the donor

When a donor arrives at the collection site, the collecting officer will request that the donor presents photographic identification and a signature for comparison. If the donor does not have acceptable photographic identification, the collecting officer will obtain a positive identification of the donor by
V. Informing the donor about the test

The donor has to be informed about the purpose and the content of the test.

VI. Consent of the donor

The donor gives his/her consent for urine collection and analysis of drugs by signature. If the donor refuses to give a sample, should that be written down to the form designated for that purpose. Appendix B gives an example of a Donor’s Statement of Informed Consent.

VII. Privacy

Procedures for collecting urine specimens shall allow individual privacy during urination and no observed collection is appropriate in normal cases. Donors have to be treated equally regardless of gender and any physical impairment. The process should avoid embarrassment but should also be rugged enough to satisfy challenge of the sample integrity.

If there is a strong suspicion of sample adulteration and/or the previous sample was adulterated the sample can be collected under the supervision of collecting officer.

VIII. Integrity of the Specimen

The collecting officer must adopt procedures to minimise the risk of adulteration of the specimen during the collection procedure. The following minimum precautions shall be taken to ensure that unadulterated specimens are obtained and correctly identified:

a. The collecting officer will ask the donor to show that their pockets are empty and remove any unnecessary outer garments such as a coat or jacket that might conceal items or substances that could be used to tamper with or adulterate the donor’s urine specimen. The collecting officer will ensure that all personal belongings such as a purse or briefcase remain with the outer garments.

b. It is recommended that the donor wash his/her hands with water only prior to urination with inspection of the hands afterwards by the collecting officer.
c. After washing hands, the donor will remain in the presence of the collecting officer and will not have access to any unregulated source of water, soap dispenser, cleaning agent, or any other materials that could be used to adulterate the specimen.

d. The donor will choose a clean specimen container. The donor may provide his/her specimen in the privacy of a toilet cubicle or otherwise partitioned area that allows for individual privacy. The collecting officer will remain outside the cubicle until the specimen is collected. The donor will be instructed not to flush the toilet until the specimen is handed to the collecting officer.

e. The collecting officer will note any unusual behaviour of the donor on the chain of custody form.

f. Upon receiving the specimen from the donor, the collecting officer will:
   - Check the volume of urine in the specimen container
     - The sufficient volume is approx. 20 millilitres (mL) or more.
     - If the volume is less than 20 mL, the specimen will be discarded and a second specimen will be collected. The donor may be offered a reasonable amount of liquid to drink for this purpose (max 2 times 250 mL in 1 hour, not to exceed a maximum of 0.5 litre). In these circumstances a donor should normally be able to provide a 20 mL urine specimen within 2 to 3 hours.
     - The samples must not be combined to provide a sufficient volume.
     - If the donor fails to provide a specimen within this time period the collecting officer will contact the appropriate authority to obtain guidance on the action to be taken.
   - Check the temperature of the urine specimen.
     - The temperature-measuring device used must accurately reflect the temperature of the specimen and not contaminate the specimen. The time from urination to temperature measurement is critical and in no case should exceed 3 minutes.
     - The acceptable range of the temperature is 32°C -38°C.
     - A temperature outside the acceptable range is a reason to be suspicious that the donor may have altered or substituted the specimen. Another specimen
European Guidelines for Workplace Drug Testing in Urine
2015-05-29 Version02

will be obtained as soon as possible and both specimens will be forwarded to the laboratory for testing.
- If there is a strong suspicion of adulteration and/or the previous sample was adulterated the sample can be collected under the supervision of a collecting officer.
  - Inspect the specimen to determine its colour and appearance for any signs of contaminants.
  - Any unusual findings will be noted on the chain of custody form.
  - If there is any reason to believe that a donor may have adulterated, altered or substituted the specimen, another specimen will be obtained as soon as possible and both specimens will be forwarded to the laboratory for testing.
  - If there is a strong suspicion of adulteration and/or the previous sample was adulterated the sample can be collected under the supervision of a collecting officer.

g) Both the donor and the collecting officer will keep the specimen container / specimen bottles in view at all times prior to the urine specimen being sealed and labelled.

h) The specimen is split into a minimum of two specimen bottles. When the specimen is transferred from the specimen container to the specimen bottles, it will be poured and the collecting officer will request the donor to observe the transfer of the specimen and the attachment of the tamper-evident seal/tape on the bottles. The tamper-evident seal ensures that any tampering with the specimen will be evident to laboratory personnel during the laboratory receipt.

i) Direct contact tests (e.g. pH) can only be carried out on the residue of the specimen after the sample has been split and sealed into specimen bottles.
  - The acceptable range of pH is 4-9. The appropriate pH measuring device covers the whole pH-range (e.g. 1-14) to be able to measure pH outside the acceptable range.
  - A pH value outside of the acceptable range is a reason to be suspicious that the donor may have altered the specimen. Another specimen will be obtained as soon as possible and both specimens will be forwarded to the laboratory for testing.
  - If there is a strong suspicion of adulteration and/or the previous sample was adulterated the sample can be collected under the supervision of a collecting officer.
European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

officer.

j) A minimum of two sealed specimens together with the corresponding chain of custody documentation in a tamper evident container must be dispatched to the laboratory. One bottle will be used for the drug test while the second bottle will remain sealed at the analytical laboratory in case the donor wishes to challenge a positive result.

k) At an appropriate time after the urine specimen has been collected and sealed into the transport bottles the collecting officer will invite the donor to wash his/her hands.

l) The specimen bottle will have an identification label that contains at a minimum the date, the donor’s specimen number and the donor’s signature/initials. The collecting officer will enter all information on the chain of custody form to identify the origin of the specimen. Both specimen bottles and all pages of the chain of custody will be labelled at the time of collection with a unique identifier.

m) The collecting officer will ask the donor questions relating to the drugs and medicines consumed within a maximum of 14 days prior to the provision of the urine specimen. These questions will be specific and wide ranging covering areas such as medications prescribed or dispensed by a doctor, dentist or hospital department and over-the-counter preparations. All information is written down to the chain of custody form.

n) The donor will be asked to read and sign a statement on the chain of custody form certifying that the specimen identified on the form was in fact the specimen provided by the donor and giving informed consent for the work to be undertaken. Appendix B gives an example of a Donor’s Statement of Informed Consent.

o) The collecting officer will complete the specimen chain of custody form and package with the urine specimen ready for dispatch together to the analytical laboratory as soon as possible. If the specimen is not dispatched at once, the collecting officer during storage prior to dispatch must give appropriate consideration to the temperature and security of the specimens. It is advised that the specimens should be stored at 4°C (do not freeze) whenever possible.

p) Other pages of the chain of custody form will be given/forwarded to the appropriate persons.

q) The collecting officer and the donor will be present throughout the procedures outlined in the paragraphs of this section.
European Guidelines for Workplace Drug Testing in Urine

IX. Exceptional situations

a. The donor is not able to give a sample

The donor may be offered a reasonable amount of liquid to drink for this purpose (max 2 times 250 mL in 1 hour, not to exceed a maximum of 0.5 litre). In these circumstances a donor should normally be able to provide a 20 mL urine specimen within 2 to 3 hours. If the donor fails to provide a specimen within this time period the collecting officer will contact the appropriate authority to obtain guidance on the action to be taken.

b. The donor wants to give the sample later

The collecting officer is not allowed to let the donor to leave the collection site and come back later to give a sample. The collecting officer will contact the appropriate authority to obtain guidance on the action to be taken.

c. Admission of illegal drug use

In case the donor admits illegal drug use, this should be noted on the chain of custody form.

X. Transportation to Laboratory

Collecting officers will arrange to dispatch the collected specimens to the drug-testing laboratory. The specimens will be placed in containers designed to minimise the possibility of damage during shipment and packed properly to comply with local/international mail and courier regulations for biological specimens. Since specimens and the corresponding documents are sealed in packages that would indicate any tampering during transit to the laboratory by couriers, carriers, and postal services, usually there is no requirement for documented chain of custody procedures for the transport of the package.
European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

11 Appendix B

Example of a Donor’s Statement of Informed Consent

I confirm that I have received information about the meaning and content of the drug test. I confirm that I have provided a freshly voided urine specimen to the specimen collector. I have observed the specimen being placed and sealed in the specimen bottles and I confirm that the information on this form and on the specimen labels is correct. I hereby give permission for a minimum of two sealed specimen containers to be sent to the laboratory and I consent that they be tested for evidence of drug use and for tests to be carried out to confirm the validity of the sample. Furthermore, I understand that the results will be communicated confidentially to the employer or a designated representative.

I consent to the above.

Donor’s Name (Block Capitals): _______________________________
Donor’s Signature: _______________________________
Date: _______________________________
Donor’s identifier on the specimen labels (if different from above): _______________________________
12 Appendix C

Some examples of fatal flaws in the Chain of Custody

1. A unique identifier (e.g. barcode) mismatches or absent
2. No documentation received with the sample
3. No written consent to test from the donor
4. Seals broken or tampered with on any bottle
5. No seals
6. Only 1 sample received
7. Insufficient sample for complete analysis
8. Leaking sample
13 Appendix D

Recommended Substances and Maximum Cut-Off Concentrations for Screening Tests in Urine

The purpose of the cut offs’ of listed substances is due to a longer detection time/window. It is a recommendation of upper limit for cut off concentrations.

**Laboratory Screen Test Cut-Off Concentration in urine (ng/mL)**

Should include, but not limited to:

<table>
<thead>
<tr>
<th>CORE PANEL</th>
<th>ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine group</td>
<td>500</td>
</tr>
<tr>
<td>Benzodiazepines group</td>
<td>200</td>
</tr>
<tr>
<td>Cannabis metabolites</td>
<td>50</td>
</tr>
<tr>
<td>Cocaine metabolites</td>
<td>150</td>
</tr>
<tr>
<td>Opiates (total)</td>
<td>300</td>
</tr>
<tr>
<td>EDDP (or methadone)</td>
<td>100 (300)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OPTIONAL</th>
<th>ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbiturates</td>
<td>200</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>5</td>
</tr>
<tr>
<td>LSD or metabolites</td>
<td>1</td>
</tr>
<tr>
<td>Phencyclidine</td>
<td>25</td>
</tr>
<tr>
<td>Propoxyphene or metabolites</td>
<td>300</td>
</tr>
</tbody>
</table>

**Cut-off under investigation / discussion:**

- Gammahydroxybutyrate (GHB)
- Ketamine
- Other opioids (at least oxycodone, hydromorphone, tramadol, fentanyl, tilidine)
- Pregabalin
- Synthetic cannabinoids
- Synthetic cathinones (MDPV etc.)
- Z-Drugs (Zopiclon, Zolpidem, Zaleplon)
Note:

1. The laboratory has to take into account country-specific differences in the drug-panel they are using.
2. These recommended cut-off values may be subject to change as advances in technology or other considerations warrant identification of these substances at other concentrations.
3. Cut-off levels for substances not indicated in Appendix D will need to be agreed with the customer taking into account the performance of the assays to be used. The toxicologist/laboratory have to explain the meaning to the customer.
4. When using immunological analyses the differences in cross-reactivity of different substances have to be noted.
5. The laboratory is responsible for remaining up to date with local drug trends and has a responsibility to use this knowledge to advise the customer of the most appropriate substances to be included in the drug testing panel.
14 Appendix E

Recommended Substances and Maximum Cut-Off Concentrations for Confirmation Tests in Urine

The purpose of the cut offs’ of listed substances is due to a longer detection time/window. It is a recommendation of upper limit for cut off concentrations.

<table>
<thead>
<tr>
<th>Confirmation Test Cut-Off Concentration in urine (ng/mL)</th>
<th>ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amphetamines</strong> (should include but not limited to:)</td>
<td></td>
</tr>
<tr>
<td>Amphetamine (d+ l)</td>
<td>200</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>200</td>
</tr>
<tr>
<td>MDA</td>
<td>200</td>
</tr>
<tr>
<td>MDA</td>
<td>200</td>
</tr>
<tr>
<td>Other members of the amphetamine group</td>
<td>200</td>
</tr>
<tr>
<td><strong>Benzodiazepines or their metabolites</strong> (should include but not limited to:)</td>
<td></td>
</tr>
<tr>
<td>Alprazolam</td>
<td>100</td>
</tr>
<tr>
<td>Bromazepam</td>
<td>100</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>100</td>
</tr>
<tr>
<td>Diazepam</td>
<td>100</td>
</tr>
<tr>
<td>Flunitrazepam</td>
<td>100</td>
</tr>
<tr>
<td>Flurazepam</td>
<td>100</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>100</td>
</tr>
<tr>
<td>Lormetazepam</td>
<td>100</td>
</tr>
<tr>
<td>Midazolam</td>
<td>100</td>
</tr>
<tr>
<td>Nitrazepam</td>
<td>100</td>
</tr>
<tr>
<td>Nordiazepam</td>
<td>100</td>
</tr>
<tr>
<td>Oxazepam</td>
<td>100</td>
</tr>
<tr>
<td>Phenazepam</td>
<td>100</td>
</tr>
<tr>
<td>Temazepam</td>
<td>100</td>
</tr>
<tr>
<td><strong>Opiates</strong> (should include but not limited to:)</td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>300</td>
</tr>
<tr>
<td>Codeine</td>
<td>300</td>
</tr>
<tr>
<td>6-Monoacetylmorphine</td>
<td>10</td>
</tr>
</tbody>
</table>
### European Guidelines for Workplace Drug Testing in Urine

2015-05-29 Version02

<table>
<thead>
<tr>
<th>Substance</th>
<th>Cut-off Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cannabis</strong></td>
<td></td>
</tr>
<tr>
<td>Cannabis metabolite (THC-COOH)</td>
<td>15</td>
</tr>
<tr>
<td><strong>Cocaine</strong></td>
<td></td>
</tr>
<tr>
<td>Cocaine metabolite (Benzylecgonine)</td>
<td>150</td>
</tr>
<tr>
<td><strong>Methadone</strong></td>
<td></td>
</tr>
<tr>
<td>Methadone (d+I)</td>
<td>250</td>
</tr>
<tr>
<td>EDDP</td>
<td>75</td>
</tr>
<tr>
<td><strong>Other drugs</strong></td>
<td></td>
</tr>
<tr>
<td>Barbiturates</td>
<td>250</td>
</tr>
<tr>
<td>Buprenorphine or metabolite</td>
<td>2</td>
</tr>
<tr>
<td>LSD or metabolites</td>
<td>1</td>
</tr>
<tr>
<td>Phencyclidine</td>
<td>25</td>
</tr>
<tr>
<td>Propoxyphene or metabolites</td>
<td>300</td>
</tr>
</tbody>
</table>

**Cut off under investigation / discussion:**

- Gamma-hydroxybutyrate (GHB)
- Ketamine
- Other opioids (at least Oxycodone, Hydromorphone, Tramadol, Fentanyl, Tildine)
- Pregabalin
- Synthetic cannabinoids
- Synthetic cathinones (MDPV etc.)
- Zaleplon
- Zolpidem
- Zopiclone

**Note:**

1. The laboratory has to take into account country-specific differences in the drug-panel they are using.
2. These recommended cut-off values may be subject to changes as advances in technology or other considerations warrant identification of these substances at other concentrations.
3. Cut-off levels for substances not indicated in Appendix E will need to be agreed with the customer taking into account the performance of the assays to be used. The toxicologist/laboratory has to explain the relevance of the cut-offs to the customer.
4. The laboratory is responsible for keeping abreast of local drug trends and advising the customer regarding relevant drugs for inclusion in the drug testing panel.
5. The Limit of Quantification (LOQ) for each drug has to be no more than 50% of the confirmation cut off level.
6. The laboratory has to be able to determine d- and l-amphetamines, if required.